Image Credit: Adobe Stock Images/ChickyKai.com
DKSH, a provider of market expansion services for pharmaceutical companies and distributor of healthcare products, is joining forces with Kyowa Kirin, a specialty pharma company, following Kyowa Kirin’s plan to grow its business in the Asia-Pacific.1
The partnership is headlined by a promotion and distribution agreement that provides DKSH with commercial rights of Kyowa Kirin’s medicines portfolio across the Taiwan region, Singapore, South Korea, Singapore, Thailand, Malaysia and Hong Kong & Macau SAR. One of the products on the list includes Poteligeo (in Singapore), along with Crysvita (in Singapore, Thailand, Malaysia and Hong Kong & Macau SAR).
As a Kyowa Kirin strategic partner, DKSH will be laying out a “full agency alliance business model” that highlights healthcare access to patients, while also providing end-to-end healthcare solutions. DKSH’s commercial distribution expertise—along with its nephrology knowledge—will be paramount for moving patient care and accessibility forward.
“We are thrilled to embark on this brand-new partnership with Kyowa Kirin, especially as they chose DKSH as a regional partner across 6 markets,” noted Bijay Singh, global head business unit healthcare and member of the executive committee for DKSH. “This collaboration reflects DKSH’s commitment to driving growth for our clients, while at the same time, pursuing our mission of providing better healthcare to all patients in our markets. By combining our expertise and resources with Kyowa Kirin’s excellent brands, we are confident we can provide a more cost-effective yet high quality commercial access solution that provides outstanding patient outcomes and customer service.”
Kyowa Kirin’s are also feel assured that they made the right decision in entering this partnership.
“We are very confident about this new journey with DKSH,” said Abdul Mullick, PhD, Kyowa Kirin’s chief international business officer. “Given DKSH’s proven healthcare expertise and commercial strength across Southeast Asia and North Asia, we are convinced we have chosen the right business partner to continue serving our patients, taking care of our employees and making people smile.”
In other news, via its performance materials division, DKSH has acquired Elite Organic, a provider of ingredients and services to the pharmaceutical industry, catering to manufacturers across the United States, Europe, Japan, and Asia.2 The company is now a part of DKSH’s current operations.
“By consistently delivering value and maintaining strong relationships with customers and suppliers, Elite Organic has earned an excellent market reputation over around 30 years,” commented Phoon Khye Wang, president at Elite Organic. “By joining DKSH, we will be able to further strengthen our strong position and expand our presence in the resilient life science industries.”
Thomas Sul and Natale Capri, co-heads, business unit performance materials, DKSH, added that, “We are very pleased to acquire Elite Organic, which offers a strong product portfolio with excellent growth prospects in Malaysia. We warmly welcome Mr. Phoon and his team at Elite Organic and look forward to further developing the business together.”
References
1. DKSH and Kyowa Kirin Forge Strategic Partnership Across Asia-Pacific. PR Newswire. August 5, 2024. Accessed August 5, 2024. https://www.prnewswire.com/apac/news-releases/dksh-and-kyowa-kirin-forge-strategic-partnership-across-asia-pacific-302214003.html
2. DKSH Performance Materials Expands its Life Science Business in Malaysia by Acquiring Elite Organic Sdn. Bhd. PR Newswire. April 8, 2024. Accessed August 5, 2024. https://www.dksh.com/na-en/home/media/news?id=en-7b2dd405-66bb-43ba-b865-13ca589090ea:2